Shopping Cart (0)
My Account

Your Shopping Cart
Metabomeeting 2014Drug Discovery India 2014Enabling Genomic Technologies and Screening Asia 2014Drug Metabolism & Discovery ADMETIndian Lab Automation20% Discount OfferePoster Award PrizeBlogs

Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report

Publisher: Select Biosciences
Published: January 2011
Pages: 139


This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.

Cancer vaccines can be generated using a number of different approaches and this report describes these approaches vis-à-vis their advantages and disadvantages and associated technical characteristics. Indeed, the FDA-approval of a cancer vaccine for prostate cancer in 2010 was a key milestone in this space and a driver for R&D efforts forward. This report presents the pre-clinical pipeline, early-stage clinical trial pipeline, and the late-stage clinical pipeline for the cancer vaccines space. Also presented are the failed vaccine candidates with a discussion about these failures and how the industry can benefit via a deeper understanding of what components are required for effective immune system activation in vivo and effective vaccination—either preventative or therapeutic.

This report also examines the technology and market landscape for circulating tumor cells (CTCs). There is currently much interest in CTCs as they may offer a highly-sensitive biomarker for cancer detection via a minimally-invasive route. The cancer research field is currently seeking to understand the role of CTCs in metastases and in this vein this report is highly-useful in that it frames the biology of CTCs, characteristics of CTCs, methodologies for CTC enrichment, CTC detection, and analytical methods. This report also snapshots the clinical trials being conducted currently involving CTCs.

Extensive Worldwide Technical and Market Analyses Presented in this Report:

  • Classification and Characterization of Cancer Vaccines
  • Various Approaches for the Generation of Cancer Vaccines
  • Anti-Cancer Vaccination Strategies
  • Tumor Associated Antigens (TAAs)
  • Tumor Specific Antigens (TSAs)
  • Failed Anti-Cancer Vaccine Candidates and Reasons for such Failure
  • Strategies to Improve Success of Cancer Vaccines
  • US FDA-Approved Cancer Vaccines
  • Therapeutic Cancer Vaccines Approved in Various Countries Around the World
  • Cancer Vaccine Pipeline in Late-Stage Clinical Trials
  • Cancer Vaccine Pipeline in Early-Stage Clinical Trials
  • Pre-Clinical Cancer Vaccine Pipeline
  • Personalized Cancer Vaccination Strategies
  • Biology and Characteristics of CTCs
  • Methodologies/Various Technologies for Enrichment, Detection, and Characterization of CTCs
  • More details of the scope of coverage of this industry report are found in the Table of Contents (TOC) for the report—see below for link to downloadable PDF of the TOC

Report Table of Contents (TOC) [Click Here to Download PDF File]

For enquiries about this market report, please contact Kathy Gray at

Conference News
Papers Presented in the Lab-on-a-Chip Asia- Microfluidics * Point-of-Care Diagnostics conference can be Published in CSBJ
Papers Presented in the Lab-on-a-Chip Asia- Microfluidics * Point-of-Care Diagnostics conference can be Published in CSBJ
Computational and Structural Biotechnology Journal [CSBJ (ISSN 2001-0370)] will devote a conference special issue comprising of selected articles from the speakers/oral and poster presenters of Lab-on-a-Chip Asia- Microfluidics * Point-of-Care Diagnostics conference. Selected authors will receive an invitation to submit full length manuscripts to CSBJ. The full length manuscripts will undergo the peer-review process as per CSBJ policies. From July-2014, CSBJ will be part of ELSEVIER Open-access

“The Medical Association of Saxony certificates the two-day congress with 16 continuing education points.”

Keynote Speakers Confirmed, Carlos Caldas and Mark Caulfield
We are thrilled to announce that Professor Carlos Caldas, Group Leader at the Cancer Research UK Cambridge Institute and Professor Mark Caufield, Chief Scientist of the Genomics England 100,000 project, have both confirmed their keynote presentations at Personalized Medicine in May 2015, Cambridge.

Keynote Speaker Confirmed, Stephen Minger
We are thrilled to announce that Stephen Minger, Global Director of GE Healthcare, has confirmed he will be giving a keynote presentation at Stem Cells in Drug Discovery 2015.


Poster Prizes
Poster Prizes
We are happy to announce that courtesy of the Metabolomics Society we will providing 5 travel awards and a best talk award for students attending Metabomeeting who are members of the Metabolomics Society. There are five travel wards of £350 and 1 prize for the best student talk of £250. To be eligible for these awards all you need be is a student member of the Metabolomics Society. Abstracts and the talk will be judged at the meeting and awards made on the award ceremony on Friday 12th Septembe

Scroll Up
Scroll Down
Keep me updated Select Bio Blog LinkedIn Twitter